NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
6/8 — Strong
WELLBUTRIN SR (bupropion hydrochloride) by GSK is mechanisms. Approved for major depressive disorder (mdd), defined by the diagnostic, statistical manual (dsm). First approved in 1996.
Drug data last refreshed Yesterday · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WELLBUTRIN SR is an extended-release formulation of bupropion hydrochloride, an atypical antidepressant approved since 1996. It is primarily indicated for major depressive disorder and functions as a norepinephrine-dopamine reuptake inhibitor (NDRI), differing mechanistically from SSRIs. The SR (sustained-release) formulation enables once- or twice-daily dosing, improving patient adherence compared to immediate-release versions.
$6MPart D
LOE ApproachingDeclining market opportunity as LOE approaches; commercial team contraction likely with focus on defending existing market share against generics.
Mechanism of Action
mechanisms. Bupropion is a relatively weak inhibitor of the neuronal reuptake of norepinephrine and dopamine and does not inhibit the reuptake of serotonin. Bupropion does not inhibit monoamine oxidase.
Indications (3)
Worked on WELLBUTRIN SR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.